Pharma Equity Group (“PEG” or “the Company”) published its Q3 report for 2024 on the 15th of November 2024.

The following are key events that we have chosen to highlight in the report:

• Patent Protection in Japan (RNX-051)
• Solid Cost Control
• Receivable from Portinho S.A. – Valued at DKK 58m
• Directed Share Issue Strengthens the Balance Sheet

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.